Production of two COVID-19 vaccine candidates is underway in College Station, the Texas A&M University System announced Monday.
The Texas A&M System and Fujifilm Diosynth Biotechnologies, which is a subcontractor of the university system’s Center for Innovation in Advanced Development and Manufacturing, will have support from the U.S. government through Operation Warp Speed, according to a news release.
Fujifilm Diosynth Biotechnologies will produce Novavax’s vaccine candidate drug, NVX‑CoV2373, which began Phase 3 testing in the U.S. and Mexico in late December. In the third phase of clinical development of a vaccine, the drug is administered to thousands of people to be tested for safety and efficacy, according to the CDC.
Full coverage of the COVID-19 outbreak and how it impacts you